|
|
|
You can get e-magazine links on WhatsApp. Click here
|
|
|
|
|
|
Lubrizol’s microencapsulated iron outperforms in absorption & gut tolerance
|
|
Saturday, 25 October, 2025, 14 : 00 PM [IST]
|
|
Barcelona
|
New research confirms the exceptional performance of Lubrizol’s microencapsulated iron ingredient Lipofer in comparison to traditional iron sources. The in vivo study, which evaluated iron bioavailability and gastrointestinal tolerability in iron-deficient rats, found that its proprietary formulation significantly outperformed conventional options, such as ferrous sulphate, ferrous bisglycinate, and other encapsulated iron salts.
Iron deficiency anaemia (IDA) is one of the most prevalent nutritional disorders worldwide, affecting an estimated quarter of the total population (2 billion people), but around 40% of women worldwide, according to a February 2025 report by the World Health Organization (WHO). Iron deficiency is known to lead to fewer red blood cells, which reduces the blood’s ability to carry oxygen. IDA is largely caused by increased iron loss, poor absorption or insufficient dietary intake making supplementation a necessary part of the daily health routine.
Symptoms of iron deficiency anaemia can include: tiredness/lack of energy, shortness of breath, laboured heartbeat, pale skin, and headaches. However, iron supplementation often triggers gastrointestinal discomfort and a strong metallic aftertaste. Absorption also can be limited, leading to higher doses needed which can lower adherence.
Its iron is a highly concentrated, micronised, and microencapsulated iron source designed specifically to reduce the associated side effects of iron supplementation while delivering a fully absorbable mineral that is significantly easier and pleasant to digest. Packaging the active ingredient in this protective matrix ensures its stability and controlled release in the G.I. tract for maximum absorption. Moreover, this technique enhances the sensory aspect and improves its overall tolerability due to the ability to reduce interactions of non-absorbed iron with gastrointestinal mucosa and possibly gut microbiota.
Lipofer microcapsules also contains lecithin, which helps the body absorb nutrients more effectively by integrating with the fats in cell membranes. In addition, the tiny iron particles in Lipofer have a larger surface area, which also improves absorption and allows the iron to reach the intestine without causing side effects.
The Lipofer study, published July 2025 in the peer-reviewed journal Nature, in, was an animal study designed and led by Roger Marineé-Casadó, PhD, revealed the ingredient’s high level of effectiveness in reversing iron deficiency anaemia within 14 days, while also being gentle on the stomach, as measured by markers of gastrointestinal side effects.
Isabel Gómez, global marketing manager for Lubrizol Nutraceuticals, said, “The microencapsulation matrix we’ve developed ensures that iron is delivered in a controlled manner. This not only improves tolerability but also enhances the bioavailability of the mineral, as confirmed by the study’s haematological and biochemical markers. This study reinforces our commitment to developing science-driven, consumer-preferred solutions that address real nutritional challenges. Iron deficiency continues to affect billions globally, and our microencapsulated iron ingredient offers a breakthrough in both efficacy and comfort.”
Alan Connolly, global R&D manager, said, “These findings are a testament to the importance of formulation science in addressing micronutrient deficiencies. By improving both the absorption and the user experience with great-tasting iron supplements we’re bridging the gap between clinical efficacy and consumer adherence.”
|
|
|
|
|
|
|
|
|
|